PhotonPharma

About PhotonPharma

PhotonPharma Inc. is a company focused on developing innovative therapies for solid tumor cancers, with a mission to improve patient outcomes through advanced medical solutions like autologous therapy.

Products & Services

Innocell™:An autologous therapy designed for solid tumor cancers, intended to delay disease progression following or in combination with chemotherapy, immunotherapy, radiotherapy, or surgical treatment. Currently in Phase 1 clinical study for recurrent epithelial ovarian cancer to assess safety and immunogenicity.

Specialties

Autologous Therapy Solid Tumor Cancer Treatment Ovarian Cancer Research Immunotherapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 2500000 MR: - FA: 2.5 million FAN: 2500000	D: 2024-08-21 FD: 2024-08-21	-

Seed Latest

2024-08-21

$2.5M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ray Goodrich

Co-founder, CEO, CSO

D

David Maranon

Director of Research

S

Susan Yonemura

Director of Product Development

D

David Reinhold Brill

Director of Regulatory Affairs

V

Valerie Ray

Vice President of Operations

B

Beth Crump

Director of Clinical Affairs

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

PhotonPharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised